Patient profiles, treatment patterns and biomarker use in early-stage non-small cell lung cancer in Greece: the retrospective real-world INFINITY study

This retrospective chart review study captured real-world initial management strategies and patient characteristics among those diagnosed with early-stage (stages I–IIIC) non-small cell lung cancer (NSCLC) between January 2016 and December 2020 at participating hospitals in Greece. This study describes management practices prior to the era of immuno-oncology therapy (IO) and targeted therapy (TT) in ES NSCLC. 300 patients were included, with equal representation of stages I, II, and III, excluding patients enrolled in clinical trials. Observation period extended from diagnosis until development of distant metastasis, withdrawal of consent, or death. Data was collected across 16 oncology clinics between October 2021 and May 2022. Median age at diagnosis was 67 years; 74% were male and 89% had a history of smoking. Most patients (96%) had a performance status of 0–1, and 62% had non-squamous histology. Biomarker testing was limited: 46% underwent any testing, including programmed death-ligand 1 (33%), epidermal growth factor receptor (31%), and anaplastic lymphoma kinase (28%). All but three patients received treatment. Surgical resection was performed in 75% of cases and systemic treatment in 74%, predominantly chemotherapy (91%). Radiotherapy was given to 29%. Overall, 68% received ≥ 2 treatment modalities. Among stage III patients, treatment appeared variable: 42% received definitive chemoradiotherapy without surgery, while among those who underwent surgery, 71% received adjuvant systemic treatment, 20% neoadjuvant, and 5% both. Most patients were treated with guideline-concordant modalities. These findings provide an essential historical baseline for evaluating evolving management patterns as novel systemic therapies are adopted into routine practice.

Authors

Institutions

Publication Details

Journal
Scientific Reports
Published
2026-11-17
DOI
https://doi.org/10.1038/s41598-026-75324-3
Primary Topic
Lung Cancer Diagnosis and Treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Patient profiles, treatment patterns and biomarker use in early-stage non-small cell lung cancer in Greece: the retrospective real-world INFINITY study

Mountzios Giannis, Boukovinas Ioannis, I. Dimitriadis, Eleni G. Iliopoulou et al.
Scientific Reports
Lung Cancer Diagnosis and Treatment
article

Patient profiles, treatment patterns and biomarker use in early-stage non-small cell lung cancer in Greece: the retrospective real-world INFINITY study

Mountzios Giannis, Boukovinas Ioannis, I. Dimitriadis, Eleni G. Iliopoulou, Georgios S. Goumas, Koumarianou Anna, Christos Christodoulou, Agelaki Sofia, Kosmidis Paris, Ramfidis Vasileios, Bafaloukos Dimitrios, Linardou Ηelena, Korantzis Ippokratis, Zagouri Flora, Mauri Davide, Emmanouilides Christos, Desiniotis Andreas, Syrigos N. Konstantinos, Demiri Stamatia
article en

Abstract

This retrospective chart review study captured real-world initial management strategies and patient characteristics among those diagnosed with early-stage (stages I–IIIC) non-small cell lung cancer (NSCLC) between January 2016 and December 2020 at participating hospitals in Greece. This study describes management practices prior to the era of immuno-oncology therapy (IO) and targeted therapy (TT) in ES NSCLC. 300 patients were included, with equal representation of stages I, II, and III, excluding patients enrolled in clinical trials. Observation period extended from diagnosis until development of distant metastasis, withdrawal of consent, or death. Data was collected across 16 oncology clinics between October 2021 and May 2022. Median age at diagnosis was 67 years; 74% were male and 89% had a history of smoking. Most patients (96%) had a performance status of 0–1, and 62% had non-squamous histology. Biomarker testing was limited: 46% underwent any testing, including programmed death-ligand 1 (33%), epidermal growth factor receptor (31%), and anaplastic lymphoma kinase (28%). All but three patients received treatment. Surgical resection was performed in 75% of cases and systemic treatment in 74%, predominantly chemotherapy (91%). Radiotherapy was given to 29%. Overall, 68% received ≥ 2 treatment modalities. Among stage III patients, treatment appeared variable: 42% received definitive chemoradiotherapy without surgery, while among those who underwent surgery, 71% received adjuvant systemic treatment, 20% neoadjuvant, and 5% both. Most patients were treated with guideline-concordant modalities. These findings provide an essential historical baseline for evaluating evolving management patterns as novel systemic therapies are adopted into routine practice.

Scientific Reports
National and Kapodistrian University of Athens (GR), Interbalkan Medical Center (GR), Hellenic Air Force (GR), St. Luke's Hospital (GR), Hellenic Airforce General Hospital (GR), Alexandra Hospital (GR), St Savas Hospital (GR), Hygeia Hospital (GR), University Hospital of Heraklion (GR), University General Hospital Attikon (GR), University Hospital of Ioannina (GR), Metropolitan Hospital (GR), Henry Dunant Hospital (GR), Sotiria General Hospital (GR), MSD (Greece) (GR)
Lung Cancer Diagnosis and Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon